🇺🇸 FDA
Pipeline program

RO7204239, GYM329 Placebo

BN43703

Phase 2 small_molecule active

Quick answer

RO7204239, GYM329 Placebo for Facioscapulohumeral muscular dystrophy (FSHD) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Facioscapulohumeral muscular dystrophy (FSHD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials